The product grade identified as Toxogonin (obidoxime chloride, DMO₄) is supplied as a crystalline veterinary active pharmaceutical ingredient for downstream manufacture into tablets, injections, capsules, powders, granules, premix, and aqueous solutions. The compound is chemically designated as 1,1′-[oxybis(methylene)]bis{4-[(E)-(hydroxyimino)methyl]pyridinium} dichloride and is identified by CAS 114-90-9 with a raw molecular formula C₁₄H₁₆Cl₂N₄O₂ and a relative molecular mass of 359.21 g/mol. The DMO₄ model code denotes the bis-quaternary oxime geometry: two pyridinium rings are linked through an oxydimethylene bridge, and each ring carries an aldoxime substituent. This structural arrangement differs from pralidoxime chloride, which contains a single pyridinium ring and one aldoxime group, and from trimedoxime bromide, which uses a propylene bridge rather than the oxydimethylene bridge of obidoxime. The API is intended only as a starting material for licensed veterinary medicinal product manufacture or extemporaneous compounding under the relevant veterinary prescription framework; it is not a finished dose. Manufacturing and release testing are expected to follow EU GMP Part II / ICH Q7 and the applicable national veterinary drug requirements.

The compound may also be described by the synonym bis(4-hydroxyiminomethylpyridinium-1-ylmethyl) ether dichloride; the DMO₄ designation is used interchangeably with toxogonin in technical literature. The API is supplied as a white to off-white crystalline powder. For veterinary use, the material is not subject to a human pharmacopoeial monograph in all territories; where a specific obidoxime chloride monograph is absent, release is performed using in-house methods validated according to ICH Q2(R1) and cross-referenced to the general chapters of Ph. Eur. or USP. The chemical structure contains two permanent quaternary ammonium centres, which creates a highly polar, water-soluble salt at veterinary formulation pH values. Packaging must include a moisture barrier and a desiccant where long-term storage above 25°C is anticipated.

Representative release criteria applied to this veterinary API include chromatographic assay of 98.0–102.0% on the anhydrous basis, total related substances ≤1.0%, water content ≤0.5%, sulfated ash ≤0.1%, and residual solvents controlled according to Ph. Eur. 5.4 or USP <467>. Elemental impurities are assessed by ICH Q3D risk evaluation for intended oral or parenteral veterinary routes. The principal pharmacological use is reactivation of organophosphate-inhibited acetylcholinesterase in companion and food-producing animals following exposure to organophosphate insecticides or nerve agents; species, dose, route, and supportive atropine therapy are determined by the responsible veterinarian and the finished product licence.

What differentiates the DMO₄ architecture from mono-oxime reactivators in veterinary formulation?

The bis-quaternary structure imposes two formulation-relevant consequences. First, the molecule exists predominantly as a highly hydrophilic cation at physiological pH because both pyridinium nitrogen atoms are permanently charged. This low lipophilicity restricts passive diffusion through lipid membranes and tends to confine the compound to extracellular water and renal elimination, a behaviour distinct from more lipophilic oxime derivatives that penetrate tissues more readily. Second, the two aldoxime groups provide two nucleophilic centres capable of reactivating organophosphate-inhibited acetylcholinesterase; the bridge length and ether oxygen alter the distance and rotational freedom between these centres. In comparative in vitro reactivation assays using bovine erythrocyte acetylcholinesterase and structurally distinct organophosphate inhibitors, obidoxime chloride shows inhibitor-dependent reactivation that may exceed pralidoxime chloride for some agents but be inferior for others. Published numerical reactivation rate constants for target veterinary species under field poisoning conditions are limited; extrapolation from human antidote literature should therefore be confirmed by species-specific enzyme kinetic studies before setting a formulation dose.

For tablet and premix applications, the permanent positive charge can influence electrostatic interaction with anionic tablet excipients and lignocellulosic feed carriers. Development batches must include content-uniformity and assay recovery studies across the intended blend range because adsorption to feed matrices can reduce extractable assay when water or neutral solvent is used. Acidified extraction solvents are preferred for analytical recovery. In solution, both oxime substituents can undergo acid-catalysed E/Z isomerisation and base-catalysed decomposition; this is why pH control is more critical for obidoxime chloride than for many neutral crystalline APIs. For veterinary premix and drinking water products, rapid dissolution of the salt is an operational advantage, but the resultant acidic pH can react with carbonates in hard water; formulators should assess precipitation in field water of representative hardness.

Wet granulation moisture limits and dry-blend homogeneity in low-dose tablets and capsules

For solid oral dosage forms, obidoxime chloride may be processed by direct compression, dry granulation, or wet granulation. The crystalline powder is hygroscopic; production-scale batch records indicate that uncontrolled exposure above 60% relative humidity can increase caking and reduce sieve throughput on a 0.5 mm oscillating sieve. When aqueous wet granulation is used, the granulating solution should be buffered to an acidic pH below 5.0; alkaline granulation media tend to accelerate oxime degradation and should be avoided. Pre-drying in a vacuum tray dryer at 40–45°C to a final moisture content of ≤0.5% by Karl Fischer titration (Ph. Eur. 2.5.12) is applied before lubrication and compression. A high-shear granulator with a 10–25 L bowl, main impeller tip speed 2–6 m/s, and chopper 1500–3000 rpm can be used for wet massing; water addition must be stopped before the granulation endpoint exceeds a power draw indicative of overwetting. Dry blending of low-dose tablets containing 0.5–2.0 wt% obidoxime chloride requires geometric dilution or a staged tumble blend in a twin-shell blender at 50–70% fill volume and 15–25 rpm for 15–20 min; overblending can induce electrostatic segregation. Content uniformity is assessed according to Ph. Eur. 2.9.40 or USP <905>. Rotary tablet compression on 8–16-station presses typically uses precompression 2–5 kN and main compression 8–15 kN; tablet hardness and disintegration are confirmed against the finished product specification. Capsule filling on an automatic dosator machine may require forced feeders and low-moisture lactose or mannitol-based fills to maintain plug integrity; batch-to-batch variation in particle size distribution is controlled by laser diffraction according to ISO 13320:2020, with acceptance ranges tied to the specific capsule fill weight and target assay.

In low-dose premix and powder applications, the limiting analytical attribute shifts from blend uniformity to detectability and carry-over. At incorporation rates commonly below 1 kg/tonne in medicated feed, the API should be milled to a controlled particle size and pre-blended with a mineral or lactose carrier before addition to the main mixer. Sampling plans follow ISO 6497:2002 for animal feeding stuffs or the relevant national premix regulation because USP <905> uniformity criteria are designed for pharmaceutical dosage forms rather than feed premixes. Carry-over in multi-product feed mills is controlled by documented cleaning validation with swab and rinse limits expressed as maximum allowable carryover; where a dedicated facility is not available, sequential production records should demonstrate that residual obidoxime chloride does not exceed the carry-over threshold established by toxicological and therapeutic carryover assessments.

Solid-state characterisation by X-ray powder diffraction and differential scanning calorimetry is performed because crystalline habit influences milling behaviour and compactibility. The product is controlled for particle size distribution by laser diffraction; typical release targets are D₉₀ below 150 µm for direct compression and below 75 µm for low-dose premix, while finer milling below 20 µm is generally avoided because of increased electrostatic adhesion and flow reduction. These targets are set from formulation-specific studies rather than a universal monograph limit.

When aseptic filtration replaces terminal sterilization for parenteral presentations

Parenteral solutions and powders for injection demand a separate impurity-control strategy. Obidoxime chloride is generally soluble in water for injection at working concentrations, but the stability of the aldoxime group is pH- and temperature-sensitive. Aseptic filtration through a 0.22 µm sterilising-grade membrane is often preferred over terminal steam sterilisation because moist-heat exposure at 121°C for 15 min can raise related substances unless a substantial degradation-kinetic data package justifies the cycle. Formulation batches for injectable use are typically buffered in the acidic range, commonly pH 3.0–4.5; the exact pH target is established by accelerated stability studies under ICH Q1A(R2). For injection-grade API, bacterial endotoxin limits are calculated from the maximum dose and animal body weight using Ph. Eur. 2.6.14 or USP <85>; no single fixed limit is universally applicable. Injectable solutions should be filled under low-oxygen headspace and protected from light, with dissolved oxygen and colour examined as stability indicators. Buffer selection should avoid phosphate or carbonate species above pH 6.5; citrate or acetate buffers are common alternatives.

For oral solution and drench presentations, obidoxime chloride is dissolved in purified water and adjusted to an acidic pH; unbuffered solutions can drift toward alkaline pH during storage, accelerating hydrolytic loss of the oxime function. Stability studies should include assay, related substances, pH, and visible particulate matter at 25°C/60% RH and 40°C/75% RH according to ICH Q1A(R2). The product is incompatible with strong oxidising agents and strongly alkaline media; any formulation containing carbonate, phosphate, or ammonia buffers above pH 6.5 is likely to reduce assay and increase deoximated degradation products. For bulk storage, the API should be kept in double polyethylene bags inside a sealed aluminium foil laminate at 2–8°C and protected from moisture. Production suites without humidity control should pre-condition the material before bag opening and use a nitrogen purge in the dispensing isolator.

Assay and related substances are determined by reversed-phase ion-pair HPLC with UV detection; the method is validated for specificity, linearity, accuracy, precision, and robustness according to ICH Q2(R1). The method can resolve obidoxime from its E/Z oxime isomers and related pyridinium degradation products when a suitable ion-pair reagent and acidified mobile phase are used. For premix recovery testing, extraction with an acidic aqueous solvent is preferred because neutral or alkaline extraction media may not fully desorb the cationic API from feed carriers and may promote hydrolysis during sample preparation.

Excipient compatibility screening for dry blends should include microcrystalline cellulose, anhydrous lactose, mannitol, pregelatinised starch, and magnesium stearate at representative ratios. Because the API is a bis-quaternary salt, high-shear blending with colloidal silicon dioxide should be evaluated for potential charge-induced agglomeration; if flow is insufficient, fumed silica levels are kept below 0.5 wt% of the final blend to avoid overblending and content uniformity loss. Scale-up from 5 kg to 100 kg blend sizes requires verification of blend homogeneity at 10 sampling points using stratified sampling and a validated thief.

Production-scale batches of low-dose quaternary ammonium salts commonly exhibit segregation during transfer from bin blenders to tablet press hoppers as the dominant content-uniformity risk, particularly when the API particle size differs from the filler. This can be mitigated by matching the API and filler size distributions, minimising drop heights, and using force feeders on rotary presses. Batch records also indicate that residual moisture above 0.8% after granulation can lead to picking and sticking on tooling at main compression forces above 15 kN; tablet formulations should therefore be compressed below that threshold unless a dedicated pre-drying step is installed.